Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after the company ...

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit ...

This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it. Charles River Laboratories’ first quarter drew a highly positive market response, with results ...

The Trump administration’s lighter regulatory touch is spurring more corporate bosses to rev up potential dealmaking, he says ...

Review the current Charles River Laboratories International Inc (CRL:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if CRL is the best investment ...

The global drug discovery services market is projected to grow at a CAGR of 15% from 2025 to 2030. This growth is driven by ...

IQVIA (IQV) stock and Medpace (MEDP) stock soar, sending their pees such as Charles River (CRL) higher as the duo beat the consensus with Q2 results. Read more here.

Charles River Laboratories International Inc. research and ratings by Barron's. View CRL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Check out our CRL stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.